Literature DB >> 36111726

[The TXNIP/Trx-1/GPX4 pathway promotes ferroptosis in hippocampal neurons after hypoxia-ischemia in neonatal rats].

Xin-Yue Zhang1, Chen-Meng Liu1, Yu-Hui Ma1, Nan Meng1, Jing-Ying Jiang, Xiao-He Yu, Xiao-Li Wang1.   

Abstract

OBJECTIVES: To observe the change in ferroptosis in hippocampal neurons after hypoxia-ischemia (HI) in neonatal rats and investigate the related mechanism based on the TXNIP/Trx-1/GPX4 signaling pathway.
METHODS: Healthy neonatal Sprague-Dawley rats, aged 7 days, were randomly divided into three groups: sham-operation (n=30), hypoxic-ischemic brain damage (HIBD) (n=30) and siRNA (TXNIP siRNA) (n=12). The classic Rice-Vannucci method was used to establish a neonatal rat model of HIBD. At 6 hours, 24 hours, 72 hours, and 7 days after modeling, Western blot was used to measure the protein expression of GPX4 in the hippocampal tissue at the injured side; at 24 hours after modeling, laser speckle imaging combined with hematoxylin-eosin staining was used to determine whether the model was established successfully; NeuN/GPX4 and GFAP/GPX4 immunofluorescence staining combined with Western blot and other methods was used to measure the protein expression of GPX4 and the signal molecules TXNIP and Trx-1 in the hippocampal tissue at the injured side; the kits for determining the content of serum iron and tissue iron were used to measure the change in iron content; quantitative real-time PCR was used to measure the mRNA expression of TXNIP, Trx-1, and GPX4.
RESULTS: At 6 hours, 24 hours, 72 hours, and 7 days after modeling, the HIBD group had a significantly lower protein expression level of GPX4 than the sham-operation group (P<0.05). At 24 hours after modeling, the HIBD group had a significantly lower cerebral blood flow of the injured side than the sham-operation group (P<0.05), with loose and disordered arrangement and irregular morphology of hippocampal CA1 neurons at the injured side. Compared with the sham-operation group, the HIBD group had a significantly higher number of TXNIP+ cells and significantly lower numbers of Trx-1+ cells and NeuN+GPX4+/NeuN+ cells in the hippocampal CA1 region at the injured side (P<0.05), with almost no GFAP+GPX4+ cells in the hippocampal CA1 region. Compared with the sham-operation group, the HIBD group and the siRNA group had significantly higher levels of serum iron and tissue iron in the hippocampus at the injured side (P<0.05). Compared with the HIBD group, the siRNA group had significantly lower levels of serum iron and tissue iron in the hippocampus at the injured side (P<0.05). The HIBD group and the siRNA group had significantly higher mRNA and protein expression levels of TXNIP than the sham-operation group (P<0.05), and the siRNA group had significantly lower expression levels than the HIBD group (P<0.05). The HIBD group and the siRNA group had significantly lower mRNA and protein expression levels of Trx-1 and GPX4 in the hippocampus at the injured side than the sham-operation group (P<0.05), and the siRNA group had significantly higher expression levels than the HIBD group (P<0.05).
CONCLUSIONS: HI induces ferroptosis of hippocampal neurons in neonatal rats by activating the TXNIP/Trx-1/GPX4 pathway, thereby resulting in HIBD.

Entities:  

Keywords:  Ferroptosis; Hippocampus; Hypoxic-ischemic brain damage; Neonatal rat; TXNIP/Trx-1/GPX4 pathway

Mesh:

Substances:

Year:  2022        PMID: 36111726     DOI: 10.7499/j.issn.1008-8830.2205149

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  16 in total

1.  Cerebral blood flow during reperfusion predicts later brain damage in a mouse and a rat model of neonatal hypoxic-ischemic encephalopathy.

Authors:  Makiko Ohshima; Masahiro Tsuji; Akihiko Taguchi; Yukiko Kasahara; Tomoaki Ikeda
Journal:  Exp Neurol       Date:  2011-11-27       Impact factor: 5.330

2.  Neonatal Encephalopathy: Beyond Hypoxic-Ischemic Encephalopathy.

Authors:  Jeffrey B Russ; Roxanne Simmons; Hannah C Glass
Journal:  Neoreviews       Date:  2021-03

3.  Ferroptosis: an iron-dependent form of nonapoptotic cell death.

Authors:  Scott J Dixon; Kathryn M Lemberg; Michael R Lamprecht; Rachid Skouta; Eleina M Zaitsev; Caroline E Gleason; Darpan N Patel; Andras J Bauer; Alexandra M Cantley; Wan Seok Yang; Barclay Morrison; Brent R Stockwell
Journal:  Cell       Date:  2012-05-25       Impact factor: 41.582

Review 4.  Role of Thioredoxin-1 and its inducers in human health and diseases.

Authors:  Yuanyuan Liu; Nianyu Xue; Boxi Zhang; Hongming Lv; Shize Li
Journal:  Eur J Pharmacol       Date:  2022-01-12       Impact factor: 4.432

5.  Melatonin improves hypoxic-ischemic brain damage through the Akt/Nrf2/Gpx4 signaling pathway.

Authors:  Zhixian Gou; Xiaojuan Su; Xing Hu; Yue Zhou; Lin Huang; Yang Fan; Jing Li; Liqun Lu
Journal:  Brain Res Bull       Date:  2020-07-15       Impact factor: 4.077

Review 6.  Thioredoxin-Interacting Protein (TXNIP) in Cerebrovascular and Neurodegenerative Diseases: Regulation and Implication.

Authors:  Sanaz Nasoohi; Saifudeen Ismael; Tauheed Ishrat
Journal:  Mol Neurobiol       Date:  2018-02-27       Impact factor: 5.590

7.  The influence of immaturity on hypoxic-ischemic brain damage in the rat.

Authors:  J E Rice; R C Vannucci; J B Brierley
Journal:  Ann Neurol       Date:  1981-02       Impact factor: 10.422

8.  Thioredoxin-1 Rescues MPP+/MPTP-Induced Ferroptosis by Increasing Glutathione Peroxidase 4.

Authors:  Liping Bai; Fang Yan; Ruhua Deng; Rou Gu; Xianwen Zhang; Jie Bai
Journal:  Mol Neurobiol       Date:  2021-02-26       Impact factor: 5.590

Review 9.  Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases.

Authors:  Haruka Tsubaki; Ikuo Tooyama; Douglas Gordon Walker
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

10.  Genistein mitigates oxidative stress and inflammation by regulating Nrf2/HO-1 and NF-κB signaling pathways in hypoxic-ischemic brain damage in neonatal mice.

Authors:  Yuan Li; Jin-Jia Zhang; Ru-Jia Chen; Ling Chen; Su Chen; Xiao-Fei Yang; Jia-Wei Min
Journal:  Ann Transl Med       Date:  2022-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.